πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Patent portfolio

Regeneron UK Patents

Full USPTO pharma patent portfolio for Regeneron UK β€” grant dates, expiration, and drug cross-links.

Patents
837
Expiring ≀24m
26

Quick answer

Regeneron UK has 837 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 26 expire within 24 months β€” use filters for patent-cliff planning.

Page 16 of 18

  1. US 8062640

    High affinity human antibodies to PCSK9

    Expires Mon Nov 17 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 8048418

    Therapeutic methods for inhibiting tumor growth with combination of Dll4 antagonists and VEGF antagonists

    Expires Mon Oct 27 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 8043617

    Human antibodies to human IL-6 receptor

    Expires Mon Oct 20 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 8029791

    Modified chimeric polypeptides with improved pharmacokinetic properties

    Expires Mon Sep 29 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 8003103

    High affinity human antibodies to human IL-18 receptor

    Expires Mon Aug 18 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 7988967

    High affinity human antibodies to human nerve growth factor

    Expires Mon Jul 28 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 7972598

    VEGF-binding fusion proteins and therapeutic uses thereof

    Expires Mon Jun 30 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 7964377

    Nucleic acid molecule encoding a fusion polypeptide capable of binding VEGF

    Expires Mon Jun 16 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 7927583

    Receptor based antagonists and methods of making and using

    Expires Mon Apr 14 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 7919593

    Human antibodies to human delta like ligand 4

    Expires Mon Mar 31 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 7879984

    Human antibodies to human CD20 and method of using thereof

    Expires Mon Jan 27 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 7837999

    Method of increasing muscle mass with IGF-1 fusion polypeptides

    Expires Mon Nov 18 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 7820154

    Use of IL-1 antagonists to treat gout

    Expires Mon Oct 21 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 7807164

    Lyophilized VEGF antagonist formulations for intravitreal administration

    Expires Mon Sep 30 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 7794717

    High affinity human antibodies to human IL-4 receptor

    Expires Mon Sep 09 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 7781404

    IGF-1 and IGF-2 chimeric polypeptides and therapeutic uses thereof

    Expires Mon Aug 19 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 7732167

    Interferon-Ξ±/Ξ² binding fusion proteins and therapeutic uses thereof

    Expires Mon Jun 03 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 7704500

    Methods of inhibiting ascites formation with modified chimeric VEGF polypeptides

    Expires Mon Apr 22 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 7655758

    Stable liquid IL-1 antagonist formulations

    Expires Mon Jan 28 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 7635474

    VEGF-binding fusion proteins

    Expires Mon Dec 17 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 7632490

    Use of IL-1 antagonists to treat gout

    Expires Mon Dec 10 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 7632503

    Method of treating a muscle-related condition with modified IGF1 polypeptides

    Expires Mon Dec 10 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 7615220

    High affinity human antibodies to human IL-18 receptor

    Expires Mon Nov 05 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 7608261

    VEGF antagonist formulations suitable for intravitreal administration

    Expires Mon Oct 22 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 7608693

    High affinity human antibodies to human IL-4 receptor

    Expires Mon Oct 22 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 7605237

    High affinity human antibodies to human IL-4 receptor

    Expires Mon Oct 15 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 7582298

    High affinity antibodies to human IL-6 receptor

    Expires Mon Aug 27 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 7576065

    Enhancing neurotrophin-induced neurogenesis by endogenous neural progenitor cells by concurrent overexpression of brain derived neurotrophic factor and an inhibitor of a pro-gliogenic bone morphogenetic protein

    Expires Mon Aug 13 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 7572893

    IL-1 antagonist formulations

    Expires Mon Aug 06 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 7557084

    IL-18 specific polypeptides and therapeutic uses thereof

    Expires Mon Jul 02 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 7534604

    Fusion polypeptides capable of activating receptors

    Expires Mon May 14 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 7534868

    Human antibodies to human delta like ligand 4

    Expires Mon May 14 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 7531173

    Ophthalmic composition of a VEGF antagonist

    Expires Mon May 07 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 7531172

    Methods of treating diseases with a VEGF antagonist

    Expires Mon May 07 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 7524499

    Modified chimeric polypeptides with improved pharmacokinetic properties

    Expires Mon Apr 23 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 7521049

    Use of VEGF inhibitors for treatment of eye disorders

    Expires Mon Apr 16 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 7521211

    IGF-1 and IGF-2 chimeric polypeptides and therapeutic uses thereof

    Expires Mon Apr 16 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 7488806

    Human antibodies to human delta like ligand 4

    Expires Mon Feb 05 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 7482002

    Method of administering and using VEGF inhibitors for the treatment of prostate cancer

    Expires Mon Jan 22 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 7479272

    Method of administering and using VEGF inhibitors for the treatment of breast cancer

    Expires Mon Jan 15 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 7479275

    Method of administering and using VEGF inhibitors for the treatment of colorectal cancer

    Expires Mon Jan 15 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 7479273

    Method of administering and using VEGF inhibitors for the treatment of renal cell cancer

    Expires Mon Jan 15 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 7479274

    Method of administering and using VEGF inhibitors for the treatment of pancreatic carcinoma

    Expires Mon Jan 15 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 7459426

    Methods of using IL-1 antagonists to treat autoinflammatory disease

    Expires Mon Nov 27 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 7449182

    Therapeutic combination of a VEGF antagonist and anti-hypertensive agent

    Expires Mon Nov 06 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 7417134

    IL-1 receptor based cytokine traps and method of using

    Expires Mon Aug 21 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 7410781

    IL-4/IL-13 specific polypeptides and therapeutic uses thereof

    Expires Mon Aug 07 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 7399612

    VEGF-binding fusion proteins and nucleic acids encoding the same

    Expires Mon Jul 10 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Regeneron UK have?

837 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Regeneron UK patents expire?

26 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources Β· Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates β€” weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.